Non-Invasive Prenatal Testing (NIPT) Market Research Report - Global Forecast till 2027

Global Non-Invasive Prenatal Testing (NIPT) Market Research Report: By Product Type (Devices, Consumables, Others), By Techniques (Biochemical Screening Tests, Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, Others) and By End-User (Diagnostic Laboratories, Hospitals, cell DNA screening) – Forecast to 2027

ID: MRFR/HC/6899-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast

Global Non-Invasive Prenatal Testing (NIPT) Market is expected to cross USD 8,217.53 Million by 2025 at a CAGR of 12.8%

Market Synopsis

NIPT is the testing procedure done during the pregnancy period to monitor the fetal growth and related diagnosis. Annually it is predicted that around 21 million girls aged 15 to 19 years give birth in developing regions around the globe.

Thus, it is among the reasons why NIPT is needed for safe delivery of the baby.  

The birth rate is expected to increase during the forecast period.

Market Influencer

Rising cases of premature pregnancy in developing and underdeveloped countries.

Market Drivers

  • Growing global population.

  • Adoption of unhealthy lifestyle habits during pregnancy.

  • Rising awareness of non-invasive prenatal testing.

Market Restraints

  • Availability of alternative techniques for prenatal testing.

  • Less accuracy of non-invasive prenatal testing compared to the invasive prenatal testing.


By Product Type

                The global NIPT market based on product type is broadly segmented into devices, consumables, and others.

  • Devices: This segment is further sub-segmented into ultrasound devices, polymerase chain reaction instruments, microarrays, sequencing systems, and others. Ultrasound devices are generally known as a sonogram. They use the ultrasound frequency for imaging of the fetal in pregnant women. Polymerase chain reaction instruments are used to amplify the DNA sequence for the analysis of any genetic issues related to pregnant women. Microarray is used to determine the levels of genes. It helps understand the conditions and plan the treatment accordingly. Sequencing systems are automated devices used for sequencing the DNA. It helps in the identification of the genomes. Other devices include fetal doppler machine and neonatal stress testers.

  • Consumables: It segment is further segmented into assay kits & reagents, disposables, and others. Assay kits & reagents comprise of ultrasound transmission gel, cleaning solution, and others. The disposables comprises of swipes, cottons, hand gloves, ad others.

  • Others: Other consumable comprises ultrasound transducers, probes, printers, related services, and others.

By Techniques

The global NIPT market based on technique is segmented into biochemical screening tests and ultrasound detection.

  • Biochemical Screening Tests: It is used for down syndrome, aneuploidies, and other genetic disorders. The test depends mainly on evaluating hormones and other proteins produced by the placenta.

  • Ultrasound Detection: This is the most preferred and utilized technique for In this method, the ultrasound machine is used. This machine provides 2D image of the fetal. The machine uses high-frequency sound waves and their echoes. During the testing the sound pulses frequencies of the range 1 to 5 megahertz is transmitted into the body using a probe. The probe also acts as a receiver for the sound waves that are reflected from tissue surfaces. 

By Application

  • Trisomy: It is a genetic disorder with three copies of a chromosome instead of two. There are different types of trisomy, such as down syndrome, Edward syndrome, Patau syndrome, and others. NIPT helps in identifying and planning the possible treatment as per the results.

  • Microdeletion syndrome: It is a genetic disorder caused by a deletion of several genes on a certain chromosome.

  • Others: It includes pregnancy screening to monitor fetal growth. It is mostly used for non-invasive testing. It also helps in imaging the fetal in its development phases and helps in maintaining the health of the fetal as well as the patient.

By End-User

  • Diagnostic Laboratories: Diagnostic laboratories are the testing setting where the NIPT test is been carried out. The labs provide various NIPT testing services as per the requirement of the patients. The diagnostic laboratories are largest segment owing to a large number of diagnostic labs/centers that provides NIPT testing products and services.

  • Hospitals: Hospitals play a very important role in prenatal testing. It provides in house testing facility to in-house patients. It helps in prompt testing of the pregnant patient that helps accurate treatments as per the diagnoses.

  • Research Institutes: Research and developments are being done by various institutes. Studies such as free cell DNA screening are also carried out. For instance, Mayo Foundation for Medical Education and Research has published various research articles about the free cell DNA screening. This indicates that there is a potential for research and development in NIPT marketing.

By Region

  • Americas: America is the fastest-growing region owing to technological advancements in NIPT.

  • Europe: In Europe, regulatory agencies are active towards NIPT related activities which is supporting the market growth in respective regions.

  • Asia-Pacific: This is the fastest-growing market for NIPT on account of the increasing population in China and India which is approximately 1,389.61 million and about 1,311.55 million, respectively, in 2019.

  • Middle East & Africa: This region has a low share is owing to the limited technological development, restricting the growth of the NIPT market.

Key Players

  • Illumina, Inc. (US)

  • Thermo Fisher Scientific, Inc. (US)

  • General Electric Company [GE Healthcare] (US)

  • Perkinelmer, Inc. (US)

  • Agilent Technologies, Inc. (US)

  • Beijing Genomics Institute (China)

  • Hoffman-La Roche Ltd. (Switzerland)

  • Tarsa Therapeutics, Inc. (US)

  • PhytoHealth Corporation (Taiwan)

  • Laboratory Corporation of America Holdings (US)

  • Natera, Inc. (US)

  • Yourgene Health (UK)

  • Centogene Holding AG [CENTOGENE AG ] (Germany)

Frequently Asked Questions (FAQ) :

The global non-invasive prenatal testing (NIPT) market is projected to reach a valuation of USD 8,217.53 MN by 2025.

The global non-invasive prenatal testing (NIPT) market is projected to grow at approximately 12.8% CAGR during forecast period (2019-2025).

North America holds the largest share in the global non-invasive prenatal testing (NIPT) market, followed by Europe and the Asia Pacific, respectively.

Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), General Electric Company [GE Healthcare] (US), Agilent Technologies, Inc. (US), Perkinelmer, Inc. (US), Beijing Genomics Institute (China), Tarsa Therapeutics, Inc. (US), Hoffman-La Roche Ltd. (Switzerland), PhytoHealth Corporation (Taiwan), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Centogene Holding AG (Germany), and Yourgene Health (UK), are some of the major players operating in the non-invasive prenatal testing (NIPT) market.

This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.